Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
On Nov. 15, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals and On CNBC's "Mad Money Lightning Round," Jim Cramer said Navitas Semiconductor Corporation (NASDAQ:NVTS) is "losing a lot of money."
在CNBC的“疯狂金钱闪电轮”节目中，吉姆·克雷默表示，纳维塔半导体公司（纳斯达克: NVTS）“正在亏损很多。”
On Tuesday, Navitas Semiconductor announced that Dr. Ranbir Singh, formerly executive vice president at Navitas and the founder and CEO of GeneSiC Semiconductor, has been appointed to the company's board of directors.
周二，Navitas Semiconductor宣布，曾担任Navitas执行副总裁、GeneSiC Semiconductor创始人兼首席执行官的Ranbir Singh博士已被任命为公司的董事会成员。
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a "quandary. I've got to tell you, I expected sales to be better," Cramer said. "I do prefer Eli Lilly (NYSE:LLY)."
再生元制药公司（纳斯达克: REGN）是一个“进退两难。我必须告诉你，我原本期望销售会更好，”克雷默说。“我更喜欢礼来（纽交所: LLY）。
On Nov. 15, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals and Sanofi SA's (NASDAQ:SNY) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. Wolfe Research analyst Alexandria Hammond initiated coverage on Regeneron Pharmaceuticals with an Outperform rating and announced a price target of $1150.
11月15日，FDA接受了再生元制药公司和赛诺菲安万特（纳斯达克: SNY）Dupixent（杜璐单抗）用于12岁及以上患有慢性特发性荨麻疹（CSU）且病情未能通过H1抗组胺药物控制的患者的补充生物制品许可申请（sBLA）的重新提交进行审查。Wolfe研究分析师亚历山大·汉蒙德对再生元制药公司展开覆盖，给予跑赢市场评级，并宣布目标价为1150美元。
Cramer said LandBridge Company LLC (NYSE:LB) is a "winner." He recommended holding on to the stock.
克雷默表示，LandBridge 公司 LLC（纽交所: LB）是一家“赢家。”他建议继续持有该股。
On Nov. 7, LandBridge reported quarterly sales of $28.487 million, which missed the analyst consensus estimate of $33.323 million. On Dec. 4, Piper Sandler analyst Mark Lear maintained LandBridge with a Neutral rating and raised the price target from $39 to $79.
11月7日，LandBridge报告季度销售额为2848.7万美元，低于分析师平均预期的3332.3万美元。12月4日，派杰投资分析师马克·李尔维持对LandBridge的中立评级，并将目标股价从39美元上调至79美元。
Price Action:
价格行动：
- Navitas Semiconductor shares gained 4% to settle at $3.14 on Tuesday.
- Regeneron Pharmaceuticals shares fell 1.7% to close at $749.57.
- LandBridge shares gained 2.8% to close at $74.84 on Tuesday.
- 周二，纳维塔半导体股价上涨4%，收于3.14美元。
- 再生元制药公司股价下跌1.7%，收于749.57美元。
- LandBridge股价周二上涨2.8%，收于74.84美元。
- Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
- 吉姆·克莱默更喜欢联邦快递，而不是这家曾经“搞砸了很多个假期季节”的快递巨头。
Photo: Shutterstock
Photo: shutterstock
